Patrick Daly

Urban Health Today

An unblinded comparative effectiveness study found that direct oral anticoagulants (DOACs) were non-inferior to low-molecular-weight heparin (LMWH) for preventing recurrent venous thromboembolism (VTE) events among a population of patients with various cancers. The 6-month rate of VTE recurrence was 6.1% with DOACs versus 8.8% with LMWH.The study&rsquo;s first author, Deborah Schrag, MD, MPH, noted that previous trials compare specific DOACs with LMWHs. However, this trial more accurately represented routine practice by allowing physicians and patients to choose a DOAC or LMWH (or fondaparinux) and modify doses or discontinue treatment for procedures. Findings from the study were reported in JAMA.Between December 2016 and April 2020, the trial enrolled 671 patients from 67 US centers with cancer and a new diagnosis of VTE. Cancer diagnoses included invasive solid tumors, lymphoma, <a href="https://urbanhealthtoday.com/page/multiple-myeloma">multiple myeloma</a>, or chronic lymphocytic leukemia.<h3>DOACs Comparable to LMWH for Anticoagulation in Cancer Patients</h3>A total of 638 (95%) patients completed <a href="https://jamanetwork.com/journals/jama/fullarticle/2805894" target="_blank" rel="noopener">the trial</a> (median age, 64 years; 55% female), of which 330 and 308 received at least 1 dose of DOAC or LMWH, respectively. The primary endpoint was VTE recurrence at 6 months, and noninferiority for DOACs versus LMWH was defined as a less than 3% difference in the upper limit of the 1-side 95% confidence interval (CI).The between-group difference of -2.7% (95% CI, -100 to 0.7) for DOACs versus LMWH met the prespecified noninferiority threshold for preventing VTE recurrence in patients with cancer. The study&rsquo;s authors noted no statistically significant differences between the groups for 6 secondary endpoints.Major bleeding was reported in 5.2% of participants in the DOAC group versus 5.6% in the LMWH group (difference, -0.4%; 95% CI, -100 to 2.5), which did not meet prespecified noninferiority criteria. Severe adverse events occurred in 33.8% and 35.1% of DOAC and LMWH participants, respectively.Ultimately, the researchers supported using DOACs to prevent VTE recurrence after acute events in patients with cancer and highlighted the potential advantages of oral treatments versus the subcutaneously administered LMWH.Related: <a href="https://urbanhealthtoday.com/post/radiation-therapys-impact-on-neurologic-function-with-multiple-myeloma">Radiation Therapy&rsquo;s Impact on Neurologic Function With Multiple Myeloma</a>

Payton White, BS

Unraveling the Genetic Factors in Alzheimer's Disease Risk in the African American Community

Alzheimer's & Dementia

Lou Portero

CDC Guidelines Not Followed for Chlamydia and Gonorrhea, Study Finds

Female Urology

Tamara Thomas

Dr. Andrew Hertler Discusses Patient Selection for Popular Immunotherapy Drugs in Cancer Treatment

Esophageal Cancer

Latest News

DOACs or Low-Molecular-Weight Heparin for VTE in Patients With Cancer

Multiple Myeloma

Direct oral anticoagulants were non-inferior to low-molecular-weight heparin for preventing recurrent VTE in patients with multiple myeloma.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe